Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

A.O.U. Città della Salute e della Scienza58 enrolled

Overview

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Study Type

OBSERVATIONAL

Enrollment

Conditions

Refractory B-Cell Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as: * Progressive disease * Early relapse (within 12 months from response) * Recurrent relapse * Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant * Age \> 18 years * Previous treatment with Rituximab * Written informed consent Exclusion Criteria: * Patient with no complete data available for collection

Outcomes

Primary Outcomes

Overall Survival

Time to last follow-up or death

Time frame: Date of last follow-up for at least 18 months (up to 78 months)

Progression Free Survival

Time from last response to nearest relapse or follow-up

Time frame: From first response to last follow-up for at least 18 month (up to 78 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.